Lisa Stamp1, Nicola Dalbeth2. 1. Department of Medicine, University of Otago, Christchurch, 2 Riccarton Ave, P.O. Box 4345, Christchurch, New Zealand. Electronic address: lisa.stamp@cdhb.health.nz. 2. Department of Medicine, University of Auckland, Auckland, New Zealand.
Abstract
OBJECTIVE: The observed associations of hyperuricaemia with hypertension, cardiovascular disease and kidney disease are receiving increasing interest. The potential role of urate-lowering therapy in the management of these "non-gout diseases" has been raised, and in some countries it is already recommended. However, there is no consistent definition of hyperuricaemia or asymptomatic hyperuricaemia, much remains unknown about the causal role of urate in these "non-gout diseases" and there is currently a lack of evidence about the effects of urate lowering on disease progression. In addition, there is potential for serious adverse effects associated with urate-lowering therapies with recent evidence suggesting that asymptomatic hyperuricaemia may be an independent risk factor for the potentially fatal allopurinol hypersensitivity syndrome. METHODS: Pubmed was searched in January 2016 using the search term "asymptomatic hyperuricaemia". RESULTS AND CONCLUSIONS: Herein, we discuss the issues related to treating asymptomatic hyperuricaemia, which at present seems premature.
OBJECTIVE: The observed associations of hyperuricaemia with hypertension, cardiovascular disease and kidney disease are receiving increasing interest. The potential role of urate-lowering therapy in the management of these "non-gout diseases" has been raised, and in some countries it is already recommended. However, there is no consistent definition of hyperuricaemia or asymptomatic hyperuricaemia, much remains unknown about the causal role of urate in these "non-gout diseases" and there is currently a lack of evidence about the effects of urate lowering on disease progression. In addition, there is potential for serious adverse effects associated with urate-lowering therapies with recent evidence suggesting that asymptomatic hyperuricaemia may be an independent risk factor for the potentially fatal allopurinolhypersensitivity syndrome. METHODS: Pubmed was searched in January 2016 using the search term "asymptomatic hyperuricaemia". RESULTS AND CONCLUSIONS: Herein, we discuss the issues related to treating asymptomatic hyperuricaemia, which at present seems premature.
Authors: Arrigo F G Cicero; Federica Fogacci; Raffaele Ivan Cincione; Giuliano Tocci; Claudio Borghi Journal: Med Princ Pract Date: 2020-10-09 Impact factor: 1.927
Authors: Xue Li; Xiangrui Meng; Maria Timofeeva; Ioanna Tzoulaki; Konstantinos K Tsilidis; John PA Ioannidis; Harry Campbell; Evropi Theodoratou Journal: BMJ Date: 2017-06-07
Authors: Meliha C Kapetanovic; Peter Nilsson; Carl Turesson; Martin Englund; Nicola Dalbeth; Lennart Jacobsson Journal: Arthritis Res Ther Date: 2018-08-29 Impact factor: 5.156
Authors: Viera Stubnova; Ingrid Os; Aud Høieggen; Marit D Solbu; Morten Grundtvig; Arne S Westheim; Dan Atar; Bård Waldum-Grevbo Journal: BMC Cardiovasc Disord Date: 2019-01-05 Impact factor: 2.298
Authors: Caroline L Benn; Pinky Dua; Rachel Gurrell; Peter Loudon; Andrew Pike; R Ian Storer; Ciara Vangjeli Journal: Front Med (Lausanne) Date: 2018-05-31